130 related articles for article (PubMed ID: 19013118)
21. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs M; Blacklock H; Bell R; Simeone JF; Reitsma DJ; Heffernan M; Seaman J; Knight RD
J Clin Oncol; 1998 Feb; 16(2):593-602. PubMed ID: 9469347
[TBL] [Abstract][Full Text] [Related]
22. Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.
Kim JS; Han BG; Choi SO; Cha SK
Biomed Res Int; 2016; 2016():1630365. PubMed ID: 27088082
[TBL] [Abstract][Full Text] [Related]
23. Focal segmental glomerulosclerosis, crescent, and rapidly progressive renal failure.
Ramirez F; Travis LB; Cunningham RJ; Cavallo T; Rajarman S; Brouhard BH; Ellis EN
Int J Pediatr Nephrol; 1982 Sep; 3(3):175-8. PubMed ID: 7141789
[TBL] [Abstract][Full Text] [Related]
24. Multiple complications in multiple myeloma.
Basi S; Schulman G; Fogo AB
Am J Kidney Dis; 2005 Mar; 45(3):619-23. PubMed ID: 15754288
[No Abstract] [Full Text] [Related]
25. Collapsing glomerulopathy.
Schwimmer JA; Markowitz GS; Valeri A; Appel GB
Semin Nephrol; 2003 Mar; 23(2):209-18. PubMed ID: 12704581
[TBL] [Abstract][Full Text] [Related]
26. Crystalloid podocytopathy with focal segmental glomerulosclerosis in PCM: a case report.
Jeon YL; Lee WI; Choi Y; Kang SY; Kim MH; Lim SJ; Lee SH
Diagn Pathol; 2015 Dec; 10():213. PubMed ID: 26670310
[TBL] [Abstract][Full Text] [Related]
27. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
28. Collapsing glomerulopathy: a cause of noncardiogenic pulmonary edema.
Wiederkehr MR; Rogers TE; Moe OW
Am J Kidney Dis; 2002 Sep; 40(3):E10. PubMed ID: 12200827
[TBL] [Abstract][Full Text] [Related]
29. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants.
Swaminathan S; Lager DJ; Qian X; Stegall MD; Larson TS; Griffin MD
Nephrol Dial Transplant; 2006 Sep; 21(9):2607-14. PubMed ID: 16705026
[TBL] [Abstract][Full Text] [Related]
30. [FSGS collapsing variant during anabolic steroid abuse: Case Report].
Flachi M; Menghi V; Moschella MR; De Giovanni P; Montevecchi M; Cerretani D; Grimaldi D; Baraldi O; Fabbrizio B; La Manna G; Rigotti A
G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550036
[TBL] [Abstract][Full Text] [Related]
31. Focal segmental glomerulosclerosis in patients receiving lithium carbonate.
Santella RN; Rimmer JM; MacPherson BR
Am J Med; 1988 May; 84(5):951-4. PubMed ID: 3129940
[TBL] [Abstract][Full Text] [Related]
32. Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Yoshizawa H; Akimoto T; Nishino K; Inoue M; Ito C; Takeda S; Kotoda A; Tamba K; Yumura W; Muto S; Ueda Y; Kusano E
Clin Exp Nephrol; 2011 Aug; 15(4):567-71. PubMed ID: 21416249
[TBL] [Abstract][Full Text] [Related]
33. Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate).
Komada T; Morishita Y; Kitamura M; Iwazu K; Numata A; Kobayashi T; Yamamoto H; Akimoto T; Saito O; Ando Y; Takemoto F; Muto S; Yumura W; Kusano E
Intern Med; 2013; 52(12):1383-7. PubMed ID: 23774552
[TBL] [Abstract][Full Text] [Related]
34. Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate.
Neyra JA; Vaidya OU; Hendricks A; Sambandam KK
Nephron Extra; 2014 Sep; 4(3):168-74. PubMed ID: 25473406
[TBL] [Abstract][Full Text] [Related]
35. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
[TBL] [Abstract][Full Text] [Related]
36. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.
Greenwood AM; Gunnarsson R; Neuen BL; Oliver K; Green SJ; Baer RA
Nephrology (Carlton); 2017 Jul; 22(7):520-530. PubMed ID: 27170059
[TBL] [Abstract][Full Text] [Related]
37. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
Brincker H; Westin J; Abildgaard N; Gimsing P; Turesson I; Hedenus M; Ford J; Kandra A
Br J Haematol; 1998 May; 101(2):280-6. PubMed ID: 9609523
[TBL] [Abstract][Full Text] [Related]
38. Endothelin is a key modulator of progressive renal injury: experimental data and novel therapeutic strategies.
Bruzzi I; Benigni A
Clin Exp Pharmacol Physiol; 1996 Apr; 23(4):349-53. PubMed ID: 8717073
[TBL] [Abstract][Full Text] [Related]
39. Reversibility of pamidronate-associated glomerulosclerosis.
Shreedhara M; Fenves AZ; Benavides D; Stone MJ
Proc (Bayl Univ Med Cent); 2007 Jul; 20(3):249-53. PubMed ID: 17637879
[TBL] [Abstract][Full Text] [Related]
40. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.
El Karoui K; Hill GS; Karras A; Moulonguet L; Caudwell V; Loupy A; Bruneval P; Jacquot C; Nochy D
Kidney Int; 2011 Mar; 79(6):643-654. PubMed ID: 21178978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
